Effect of Mepolizumab in OCS Dependent Severe Eosinophilic Asthma Patients with History of Omalizumab Treatment

被引：0
|
作者：
Prazma, Charlene M. [1 ]
Magnan, Antoine [2 ]
Price, Robert [3 ]
Ortega, Hector [1 ]
Yancey, Steven W. [1 ]
Albers, Frank C. [1 ]
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
[2] Univ Nantes, Nantes, France
[3] GlaxoSmithKline, Stockley Pk, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2015年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2014.12.1879
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
L6
引用
收藏
页码：AB383 / AB383
页数：1
相关论文
共 50 条
  • [41] Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
    Liu, Mark C.
    Chipps, Bradley
    Munoz, Xavier
    Devouassoux, Gilles
    Bergna, Miguel
    Smith, Steven G.
    Price, Robert G.
    Galkin, Dmitry, V
    Azmi, Jay
    Mouneimne, Dalal
    Albers, Frank C.
    Chapman, Kenneth R.
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [42] MEPOLIZUMAB IN ADOLESCENTS WITH SEVERE EOSINOPHILIC ASTHMA NOT ELIGIBLE FOR OMALIZUMAB: ONE CENTRE'S EXPERIENCE
    Weir, E.
    Paton, J. Y.
    THORAX, 2017, 72 : A120 - A120
  • [43] Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
    Carpagnano, Giovanna Elisiana
    Resta, Emanuela
    Povero, Massimiliano
    Pelaia, Corrado
    D'Amato, Mariella
    Crimi, Nunzio
    Scichilone, Nicola
    Scioscia, Giulia
    Resta, Onofrio
    Calabrese, Cecilia
    Pelaia, Girolamo
    Barbaro, Maria Pia Foschino
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [44] Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
    Mark C. Liu
    Bradley Chipps
    Xavier Munoz
    Gilles Devouassoux
    Miguel Bergna
    Steven G. Smith
    Robert G. Price
    Dmitry V. Galkin
    Jay Azmi
    Dalal Mouneimne
    Frank C. Albers
    Kenneth R. Chapman
    Respiratory Research, 22
  • [45] Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
    Resta, Emanuela
    Carpagnano, Giovanna Elisiana
    Pelaia, Corrado
    D'Amato, Maria
    Crimi, Nunzio
    Scichilone, Nicola
    Calabrese, Cecilia
    Resta, Onofrio
    Scioscia, Giulia
    Pelaia, Girolamo
    Barbaro, Maria Pia Foschino
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [46] Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
    Giovanna Elisiana Carpagnano
    Emanuela Resta
    Massimiliano Povero
    Corrado Pelaia
    Mariella D’Amato
    Nunzio Crimi
    Nicola Scichilone
    Giulia Scioscia
    Onofrio Resta
    Cecilia Calabrese
    Girolamo Pelaia
    Maria Pia Foschino Barbaro
    Scientific Reports, 11
  • [47] Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience
    Lim, Y. T.
    Williams, T. C.
    Langley, R. J.
    Weir, E.
    JOURNAL OF ASTHMA, 2024, 61 (08) : 793 - 800
  • [48] Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for Omalizumab: a single centre experience
    Lim, Yu Ting
    Williams, Thomas
    Langley, Ross
    Weir, Elise
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [49] Eosinophilic refractory inflammation in OCS-dependent severe asthma
    Carriero, Vitina
    Bertolini, Francesca
    Arrigo, Elisa
    Ricciardolo, Fabio Luigi Massimo
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [50] Real life data on treatment response to mepolizumab in patients with severe eosinophilic asthma
    Ntakoula, M.
    Fokoloros, C.
    Pasali, M.
    Aggelides, X.
    Makris, M.
    ALLERGY, 2019, 74 : 446 - 446
12345